Christopher Wai Kei Lam (Christopher Wk Lam, Brian Tomlinson)

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 10

Top Topics

Low Density Lipoprotein

Cardiovascular Disease

Replacement Therapy

Monoclonal Antibody

Top Venues

Expert opinion on pharmacotherapy

Expert opinion on drug metabolism & toxicology

Cardiovascular drugs and therapy

Pharmaceutical biology

This page only lists publications with an associated author ORCID identifier.

Publications

Sze Wa Chan, Christopher Wai Kei Lam, Paul Chan, Christopher Wai Kei Lam
The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk. Pharmaceutical biology 59 (1) (2022)
Christopher Wai Kei Lam, Elaine Y K Chow, Paul Chan, Christopher Wai Kei Lam
An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. Expert opinion on drug metabolism & toxicology 17 (12) (2022)
Christopher Wai Kei Lam, Nivritti Gajanan Patil, Manson Fok, Paul Chan, Christopher Wai Kei Lam
The role of sulfonylureas in the treatment of type 2 diabetes. Expert opinion on pharmacotherapy (2021)
Christopher Wai Kei Lam, Chen-Hsiu Lin, Paul Chan, Christopher Wai Kei Lam
Personalized medicine in lipid-modifying therapy. Personalized medicine 18 (2) (2021)
Christopher Wai Kei Lam, Nivritti Gajanan Patil, Manson Fok, Christopher Wai Kei Lam
Managing dyslipidemia in patients with Type 2 diabetes. Expert opinion on pharmacotherapy 22 (16) (2021)
Christopher Wai Kei Lam, Paul Chan, Christopher Wai Kei Lam
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert opinion on pharmacotherapy (2021)
Christopher Wai Kei Lam, Paul Chan, Yuzhen Zhang, Christopher Wai Kei Lam
Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert opinion on pharmacotherapy 21 (17) (2020)
Christopher Wai Kei Lam, Paul Chan, Zhongmin Liu, Christopher Wai Kei Lam
Statin Pharmacology Revisited. Cardiovascular drugs and therapy 34 (2) (2020)
Christopher Wai Kei Lam, Paul Chan, Christopher Wai Kei Lam
Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. Expert review of endocrinology & metabolism 15 (3) (2020)
Christopher Wai Kei Lam, Paul Chan, Yuzhen Zhang, Zhongmin Liu, Christopher Wai Kei Lam
Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert opinion on drug metabolism & toxicology 16 (5) (2020)